{"id":"https://openalex.org/W1970236830","doi":"https://doi.org/10.1179/joc.1996.8.3.237","title":"Prevention of Delayed Emesis by a Single Intravenous Bolus Dose of 5-HT3-Receptor- Antagonist in Moderately Emetogenic Chemotherapy","display_name":"Prevention of Delayed Emesis by a Single Intravenous Bolus Dose of 5-HT3-Receptor- Antagonist in Moderately Emetogenic Chemotherapy","publication_year":1996,"publication_date":"1996-01-01","ids":{"openalex":"https://openalex.org/W1970236830","doi":"https://doi.org/10.1179/joc.1996.8.3.237","mag":"1970236830","pmid":"https://pubmed.ncbi.nlm.nih.gov/8808724"},"language":"en","primary_location":{"id":"doi:10.1179/joc.1996.8.3.237","doi":"https://doi.org/10.1179/joc.1996.8.3.237","is_oa":false,"landing_page_url":"https://doi.org/10.1179/joc.1996.8.3.237","pdf_url":null,"source":{"id":"https://openalex.org/S127202688","display_name":"Journal of Chemotherapy","issn_l":"1120-009X","issn":["1120-009X","1973-9478"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090814125","display_name":"B. Massidda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172446870","display_name":"University of Cagliari","ror":"https://ror.org/003109y17","country_code":"IT","type":"education","lineage":["https://openalex.org/I172446870"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"B. Massidda","raw_affiliation_strings":["Division of Medical Oncology, University of Cagliari, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, University of Cagliari, Italy","institution_ids":["https://openalex.org/I172446870"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110082669","display_name":"Maria Teresa Ionta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M.T. Ionta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.12526704,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"8","issue":"3","first_page":"237","last_page":"242"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11785","display_name":"Nausea and vomiting management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11785","display_name":"Nausea and vomiting management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12429","display_name":"Chemotherapy-induced organ toxicity mitigation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11964","display_name":"Pregnancy and Medication Impact","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chemotherapy-induced-nausea-and-vomiting","display_name":"chemotherapy-induced nausea and vomiting","score":0.8289999961853027},{"id":"https://openalex.org/keywords/delayed-emesis","display_name":"delayed emesis","score":0.7649999856948853},{"id":"https://openalex.org/keywords/5-ht3-receptor-antagonists","display_name":"5-HT3 receptor antagonists","score":0.9919999837875366},{"id":"https://openalex.org/keywords/ondansetron","display_name":"ondansetron","score":0.9900000095367432},{"id":"https://openalex.org/keywords/granisetron","display_name":"granisetron","score":0.996999979019165},{"id":"https://openalex.org/keywords/tropisetron","display_name":"tropisetron","score":1.0},{"id":"https://openalex.org/keywords/moderately-emetogenic-chemotherapy","display_name":"moderately emetogenic chemotherapy","score":0.9340000152587891},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8809999823570251},{"id":"https://openalex.org/keywords/fec-regimen","display_name":"FEC regimen","score":0.699999988079071},{"id":"https://openalex.org/keywords/cmf-regimen","display_name":"CMF regimen","score":0.9010000228881836},{"id":"https://openalex.org/keywords/epirubicin","display_name":"epirubicin","score":0.8740000128746033},{"id":"https://openalex.org/keywords/mitoxantrone","display_name":"mitoxantrone","score":0.7400000095367432},{"id":"https://openalex.org/keywords/antiemetic-prophylaxis","display_name":"antiemetic prophylaxis","score":0.7680000066757202},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.3659999966621399},{"id":"https://openalex.org/keywords/granulocyte-colony-stimulating-factor","display_name":"granulocyte colony-stimulating factor","score":0.5730000138282776}],"concepts":[{"id":"https://openalex.org/C3020190219","wikidata":"https://www.wikidata.org/wiki/Q640448","display_name":"Intravenous bolus","level":2,"score":0.6585744619369507},{"id":"https://openalex.org/C43376680","wikidata":"https://www.wikidata.org/wiki/Q6580786","display_name":"Bolus (digestion)","level":2,"score":0.6412777900695801},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6099773049354553},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5118052363395691},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5109075903892517},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4993290901184082},{"id":"https://openalex.org/C2777170512","wikidata":"https://www.wikidata.org/wiki/Q410011","display_name":"Ondansetron","level":3,"score":0.45719730854034424},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3429066836833954},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.22665590047836304},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2213301658630371},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.13019013404846191}],"mesh":[{"descriptor_ui":"D000077526","descriptor_name":"Tropisetron","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000932","descriptor_name":"Antiemetics","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000932","descriptor_name":"Antiemetics","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014839","descriptor_name":"Vomiting","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D014839","descriptor_name":"Vomiting","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016179","descriptor_name":"Granulocyte Colony-Stimulating Factor","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016179","descriptor_name":"Granulocyte Colony-Stimulating Factor","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016179","descriptor_name":"Granulocyte Colony-Stimulating Factor","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017294","descriptor_name":"Ondansetron","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017294","descriptor_name":"Ondansetron","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017829","descriptor_name":"Granisetron","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017829","descriptor_name":"Granisetron","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1179/joc.1996.8.3.237","doi":"https://doi.org/10.1179/joc.1996.8.3.237","is_oa":false,"landing_page_url":"https://doi.org/10.1179/joc.1996.8.3.237","pdf_url":null,"source":{"id":"https://openalex.org/S127202688","display_name":"Journal of Chemotherapy","issn_l":"1120-009X","issn":["1120-009X","1973-9478"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Chemotherapy","raw_type":"journal-article"},{"id":"pmid:8808724","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8808724","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of chemotherapy (Florence, Italy)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W165843277","https://openalex.org/W1965000772","https://openalex.org/W1996898160","https://openalex.org/W2003068607","https://openalex.org/W2051675546","https://openalex.org/W2087182909","https://openalex.org/W2131206836","https://openalex.org/W2131216345","https://openalex.org/W2341319633","https://openalex.org/W2946509781","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2052109081","https://openalex.org/W2319719212","https://openalex.org/W1821827363","https://openalex.org/W2048136430","https://openalex.org/W1939507303","https://openalex.org/W2033874171","https://openalex.org/W2418644999","https://openalex.org/W4253142519","https://openalex.org/W2009020541","https://openalex.org/W129177764"],"abstract_inverted_index":{"While":[0],"the":[1,33,36,122,143,150,164,173,192,199,204,211,248,271],"use":[2],"of":[3,26,35,40,52,104,133,156,179],"5-HT3":[4],"receptor":[5],"antagonists":[6],"is":[7,20,246],"clearly":[8],"justified":[9],"in":[10,43,57,121,142,149,163,172,191,198,227],"patients":[11,51],"receiving":[12,62],"cisplatin,":[13],"their":[14],"role":[15],"with":[16,261,276],"less":[17],"emetic":[18,45],"drugs":[19,213],"still":[21],"not":[22],"defined.":[23],"The":[24],"aim":[25],"our":[27],"randomized":[28,93],"study":[29],"was":[30,136,158,186,221],"to":[31,54,94,223],"verify":[32],"efficacy":[34],"single":[37],"standard":[38],"dose":[39,78,264],"three":[41,212],"5-HT3-receptor-antagonists":[42],"moderately":[44],"chemotherapies.":[46],"Sixty":[47],"chemotherapy-naive":[48],"breast":[49],"cancer":[50],"30":[53],"71":[55],"years":[56],"age,":[58],"P.S.":[59],"=":[60,230,239],"0-1,":[61],"5-fluorouracil-epirubicin-cyclophosphamide":[63],"(FEC":[64],"75)":[65],"q":[66,81],"21":[67],"days":[68,83],"or":[69,72,76,86,106,111,183],"cyclophosphamide-methotrexate-5-fluorouracil":[70],"(CMF)":[71],"120":[73],"mg/m2":[74,88],"epirubicin":[75,89],"high":[77],"mitomycin-methotrexate-mitoxantrone":[79],"(MMM)":[80],"14":[82],"(+":[84,90],"G-CSF)":[85,91],"100":[87],"were":[92,127,214],"receive,":[95],"15":[96],"min":[97],"before":[98],"chemotherapy,":[99],"8":[100],"mg":[101,108,113],"i.v.":[102,109,114],"bolus":[103],"ondansetron":[105,220],"3":[107],"granisetron":[110,224],"5":[112],"tropisetron":[115,226],"and":[116,140,145,153,161,167,170,181,189,194,225,235,268],"no":[117,207],"further":[118],"antiemetic":[119],"therapy":[120],"following":[123,272],"days.":[124],"180":[125],"cycles":[126],"evaluable.":[128],"Complete":[129,176],"protection,":[130],"(the":[131],"absence":[132,155,182],"vomiting":[134,180,218],"episodes,)":[135],"respectively":[137],"75%,":[138],"70%":[139,141],"acute":[144,165,193,217,228],"70%,":[146],"82%,":[147],"72%":[148],"delayed":[151,200,236],"phases,":[152,201],"an":[154],"nausea":[157,237],"56%,":[159],"37%":[160],"20%":[162],"phase":[166],"50%,":[168],"35%":[169],"27%":[171],"delayed,":[174],"respectively.":[175,202],"response,":[177],"(absence":[178],"mild":[184],"nausea,)":[185],"74%,":[187],"58.6%":[188],"50.8%":[190],"64%,":[195],"63.7%,":[196],"47.3%":[197],"At":[203],"statistical":[205],"analysis":[206],"significant":[208],"differences":[209],"between":[210],"found":[215],"regarding":[216],"while":[219],"superior":[222],"(p":[229],"0.018;":[231],"p":[232,241],"<":[233,242],"0.05)":[234],"(P":[238],"0.104;":[240],"0.01).":[243],"This":[244],"activity":[245],"practically":[247],"same":[249],"as":[250],"that":[251],"we":[252],"reported":[253],"(Ann":[254],"Oncol":[255],"1994;":[256],"6,":[257],"suppl":[258],"8:":[259],"204)":[260],"a":[262,277],"loading":[263],"on":[265],"day":[266],"1":[267],"maintenance":[269],"for":[270],"2-5":[273],"days,":[274],"but":[275],"significantly":[278],"favorable":[279],"cost-benefit":[280],"ratio.":[281]},"counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}